Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $288.0052W HIGH $447.03
Volume
602.37 K
Value Traded
812.26 M
Short % Float
2.61%
+2.12%Week
+5.19%1 Month
+13.26%3 Month
+17.25%6 Month
+33.74%5 Year
+98,606.32%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
223.60 B
EPS (TTM)
16.17
P/E Ratio
25.45
Ent. Value
271.32 B
Total Shares
540.63 M
Float Shares
539.40 M
Insiders
0.23%
Institutions
85.56%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
AMGN Catalyst Timeline
Dated clinical, regulatory and corporate events for Amgen Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Amgen Inc.
2418Total events
12Upcoming
962Tier-1 (high impact)
2010 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutDazodalibepClinical Data
Positive topline Phase 3 results for dazodalibep in moderate-to-severe systemic Sjögren's disease
moderate-to-severe systemic Sjögren's diseasesource ↗
▲Primary Endpoint MetDazodalibepClinical Data
OASIZ 301 met primary endpoint of change from baseline in ESSDAI at Week 48
moderate-to-severe systemic Sjögren's diseasesource ↗
▲Label ExpansionIMDELLTRAApprovedFDA Decision
FDA approves reduced monitoring time for first two doses of IMDELLTRA
extensive-stage small cell lung cancer (ES-SCLC)source ↗
▲Primary Endpoint MetIMDELLTRAApprovedClinical Data
IMDELLTRA plus IMFINZI met primary overall survival endpoint in first-line ES-SCLC
first-line extensive stage small cell lung cancersource ↗
▲Secondary Endpoint DataIMDELLTRAApprovedClinical Data
DeLLphi-305 met secondary PFS and ORR endpoints
first-line extensive stage small cell lung cancersource ↗
▲Oral PresentationRepathaApprovedPresentation
Late-breaking presentation of VESALIUS-CV mortality analysis at ESC Congress 2026
high-risk primary preventionsource ↗
▲PublicationRepathaApprovedPresentation
VESALIUS-CV mortality analysis published in Circulation
high-risk primary preventionsource ↗
●Poster PresentationRepathaApprovedPresentation
Poster on Lp(a) testing from CVMOBIUS2 Registry
atherosclerotic cardiovascular diseasesource ↗
▲Oral PresentationRepathaApprovedPresentation
Presentation of total CV events analysis
high-risk primary preventionsource ↗
●Poster PresentationRepathaApprovedPresentation
Poster on lipid management in coronary artery disease
coronary artery diseasesource ↗
▲Oral PresentationRepathaApprovedPresentation
Presentation of first MI risk analysis
high-risk primary preventionsource ↗
▲Topline ReadoutTEZSPIREApprovedClinical Data
TEZSPIRE demonstrates positive Phase 3 results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
eosinophilic esophagitissource ↗
●Quarterly UpdateTAVNEOSApprovedCorporate
Amgen continues engagement with FDA regarding TAVNEOS
▲EU ApprovalRepathaApprovedEx-US Regulatory
European Commission approved expanded indication for Repatha
established or high risk for ASCVDsource ↗
▲CHMP Positive OpinionRepathaApprovedEx-US Regulatory
CHMP positive opinion for broader use of Repatha
cardiovascular risk reduction in adults with established atherosclerotic cardiovascular disease or at high risksource ↗
▲CHMP Positive OpinionRepathaApprovedEx-US Regulatory
CHMP positive opinion for broader use of Repatha to reduce risk of first heart attack or stroke
cardiovascular risk reduction in adults with established atherosclerotic cardiovascular disease or at high risksource ↗
▲CHMP Positive OpinionRepathaApprovedEx-US Regulatory
CHMP adopted positive opinion for Repatha to reduce cardiovascular risk in adults with established or at high risk for ASCVD
atherosclerotic cardiovascular diseasesource ↗
▲IP Litigation RulingIP / Competition
Jury finds Amgen willfully infringed Harbour's Grosveld Patent, awards $20.2M damages
◆Oral PresentationPresentation
Amgen to present at Goldman Sachs 47th Annual Global Healthcare Conference
▲Oral PresentationRepathaApprovedPresentation
VESALIUS-CV subgroup results for Repatha in high-risk diabetes patients presented at ADA 2026
high-risk diabetes with elevated LDL-Csource ↗
●Oral PresentationPresentation
Real-world evidence studies on GLP-1 therapy persistence and adherence presented at ADA 2026
obesity and diabetessource ↗
▲EU ApprovalIMDYLLTRAApprovedEx-US Regulatory
EC approval of IMDYLLTRA for advanced SCLC
мелкоклеточный рак легкого на запущенной стадииsource ↗
◆Oral PresentationUPLIZNAApprovedPresentation
Natural History of IgG4-RD: Patterns of Organ Involvement and Flare-associated Biomarker Changes in the Phase 3 MITIGATE Trial (Abstract #OP052) oral presentation at EULAR 2026
IgG4-related diseasesource ↗
◆Poster PresentationUPLIZNAApprovedPresentation
Long-term Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Primary Results from Year 1 of the Open-Label Period of the Phase 3 MITIGATE Trial (Abstract #POS0440) poster presentation at EULAR 2026
IgG4-related diseasesource ↗
◆Poster PresentationTAVNEOSApprovedPresentation
Real-world evidence from AQUARIUS analyses (Abstracts #POS0135 and #POS0867) poster presentations at EULAR 2026
ANCA-associated vasculitissource ↗
▲EU ApprovalIMDYLLTRAApprovedEx-US Regulatory
European Commission grants marketing authorization for IMDYLLTRA as monotherapy for ES-SCLC
extensive-stage small cell lung cancersource ↗
◆Oral PresentationPresentation
Amgen presentation at Bank of America Merrill Lynch Global Healthcare Conference
▲Trial InitiationMariTideTrial
MARITIME-2 EXTENSION Phase 3 trial initiated for MariTide
obesitysource ↗
▲Trial InitiationOlpasiranTrial
Phase 3 OCEAN(a)-Outcomes trial initiated for olpasiran
cardiovascular diseasesource ↗
▲Trial InitiationUPLIZNAApprovedTrial
Phase 3 MITIGATE trial initiated for UPLIZNA in IgG4-RD
IgG4-related diseasesource ↗
▲Trial InitiationTEPEZZAApprovedTrial
Phase 3 trial initiated for TEPEZZA in chronic TED
chronic thyroid eye diseasesource ↗
▲Trial InitiationTAVNEOSApprovedTrial
Phase 3 ADVOCATE trial initiated for TAVNEOS in ANCA vasculitis
ANCA-associated vasculitissource ↗
▲Trial InitiationDazodalibepTrial
Phase 3 trial initiated for dazodalibep in Sjögren's syndrome
Sjögren's syndromesource ↗
▲Trial InitiationDaxdilimabTrial
Phase 2 trial initiated for daxdilimab in SLE
systemic lupus erythematosussource ↗
▲Trial InitiationTEZSPIREApprovedTrial
Phase 3 trial initiated for TEZSPIRE in COPD
chronic obstructive pulmonary diseasesource ↗
▲Trial InitiationBlinatumomabApprovedTrial
Phase 3 trial initiated for blinatumomab in B-ALL
B-cell precursor acute lymphoblastic leukemiasource ↗
▲Trial InitiationInebilizumabApprovedTrial
Phase 3 trial initiated for inebilizumab in myasthenia gravis
myasthenia gravissource ↗
▲Trial InitiationBLINCYTOApprovedTrial
Phase 3 trial initiated for BLINCYTO in B-ALL
B-cell precursor acute lymphoblastic leukemiasource ↗
▲Trial InitiationIMDELLTRAApprovedTrial
Phase 3 trial initiated for IMDELLTRA in SCLC
small cell lung cancersource ↗
Past FDA Catalysts and PDUFA Decisions
How AMGN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-11 | Uplizna (inebilizumab-cdon) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
A88 / 100
Pipeline Score
$55.1B
Pipeline Value
$169.9B
Commercial Value
Fair Value
Valuation Signal
74
Drugs Scored
0.8x
rNPV / MCap
Top 1%
Large Pharma(rank 1 of 658)
Percentile Rank
Amgen Inc. earns an A-grade pipeline score (88/100), with $55.1B risk-adjusted pipeline value, led by Maridebart cafraglutide in Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight (Phase 3).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $38.1B x 4.5 = $169.9B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Prolia | $3.7B | $4.4B | -17% |
| Repatha | $3.5B | $2.5B | +38.3% |
| EVENITY | $2.4B | $1.8B | +35% |
| Otezla | $2.1B | $2.2B | -4.9% |
| TEPEZZA | $2.1B | $1.8B | +13.6% |
| ENBREL | $2.0B | $3.0B | -31.9% |
| XGEVA | $1.7B | $2.2B | -20.5% |
| BLINCYTO | $1.7B | $1.5B | +15.7% |
| Nplate | $1.7B | $1.5B | +14.2% |
| TEZSPIRE | $1.7B | $1.2B | +40.9% |
| KRYSTEXXA | $1.4B | $1.2B | +13.6% |
| KYPROLIS | $1.4B | $1.5B | -6.7% |
Top 12 of 14 product lines shown.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Maridebart cafraglutide Small moleculeNCT07226765 | Obstructive Sleep Apnea | Phase 3 | ACTIVE NOT_RECRUITING | 250 | Sep 13, 2028 |
Clinical Trial Results
Readouts, endpoints and source filings for every AMGN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| dazodalibep | moderate-to-severe Sjögren's disease | Phase 3 | 2026-09-22 | statistically significant and clinically meaningful improvement at Week 48Read More | AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASERead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Khosla RachnaOfficer (SVP, Business Development) | Option | 1,252 7,656 held | $162.60 | 08/13/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AMGN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 0.3 % | 14.04 M | 39.90 K | -9.73% ( -4.30 K) |
AMGN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-03-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AMGN ranks across every disease it competes in
Competitive Position is a premium feature
See how AMGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAMGN News
AMGNAMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE
Amgen announced positive topline results from the Phase 3 OASIZ 301 study of dazodalibep for moderate-to-severe Sjögren's disease. The study met its primary endpoint, showing significant improvement in systemic disease activity at Week 48. This marks a potential breakthrough for patients, as there are currently no FDA-approved treatments for this debilitating autoimmune disease.
Read more →AMGNFDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®
Amgen announced that the FDA has approved a significant reduction in the monitoring time required for the first two doses of IMDELLTRA (tarlatamab-dlle) from 22-24 hours to 6-8 hours. This change aims to enhance patient access to treatment for extensive-stage small cell lung cancer by allowing for less time spent in healthcare settings. Follow-up assessments will still be conducted the day after each of the initial doses.
Read more →AMGNAMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
Amgen will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. Key executives, including Jay Bradner and Thomas Dittrich, will discuss the company's developments. The presentation will be available via webcast for the public and investors, with an archive accessible for 90 days post-event.
Read more →AMGN▼ -10.1%on this newsshared move
IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
Amgen announced that the Phase 3 DeLLphi-305 study demonstrated a significant improvement in overall survival for IMDELLTRA® in combination with IMFINZI® compared to durvalumab alone. The study also successfully met secondary endpoints, including progression-free survival and objective response rate, marking a notable advancement in treatment for extensive stage small cell lung cancer.
Read more →AMGNAMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE
Amgen will present at the 2026 Wells Fargo Healthcare Conference on September 10, 2026. Key executives, including the CFO and CMO, will participate in the presentation. The event will be available via a live webcast, allowing media and investors to access the information. The webcast will also be archived for later viewing.
Read more →AMGNAMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
Amgen announced that Repatha (evolocumab) significantly reduces the risk of death in high-risk adults without prior cardiovascular events, as shown in the Phase 3 VESALIUS-CV trial. The study, which involved over 12,000 patients, demonstrated a 20% reduction in overall mortality. These findings highlight the importance of early and intensive LDL-C lowering in preventing cardiovascular morbidity and mortality.
Read more →AMGNTEZSPIRE® DEMONSTRATES POSITIVE PHASE 3 RESULTS IN EOSINOPHILIC ESOPHAGITIS ACROSS BOTH CO-PRIMARY AND ALL KEY SECONDARY ENDPOINTS
TEZSPIRE has demonstrated positive Phase 3 results in treating eosinophilic esophagitis, showing statistically significant and clinically meaningful improvements in disease symptoms compared to placebo. The efficacy was maintained through Week 52, highlighting the drug's potential in addressing epithelial-driven inflammatory diseases. These results support the broader application of TEZSPIRE in similar conditions.
Read more →AMGNAMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS
Amgen reported strong financial results for Q2 2026, with total revenues rising 10% to $10.1 billion, driven by significant growth in key products. GAAP EPS increased 65% to $4.37, reflecting higher revenues. However, some products, like Prolia, experienced declines in sales, indicating challenges in certain segments. The company remains optimistic about future growth prospects, particularly with ongoing Phase 3 trials.
Read more →AMGNFIRST AMGEN SCHOLARS PROGRAM IN INDIA LAUNCHES AT IIIT HYDERABAD
Amgen has launched its first Scholars Program in India at IIIT Hyderabad, aimed at inspiring future scientific innovators. The program will support 10 undergraduate scholars from various countries, focusing on AI and machine learning applications in healthcare and drug discovery. This initiative reflects Amgen's commitment to advancing science education and fostering collaboration in the region.
Read more →AMGNAMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDEND
Amgen announced a dividend of $2.52 per share for the third quarter of 2026, payable on September 11, 2026. This dividend reflects the company's strong financial position and commitment to returning value to shareholders. The announcement highlights Amgen's ongoing innovation in biotechnology and its significant role in the industry.
Read more →AMGNAVIS FAVORABLE DU CMUH CONCERNANT UNE UTILISATION PLUS LARGE DE REPATHA® D'AMGEN POUR REDUIRE LES RISQUES DE PREMIER INFARCTUS DU MYOCARDE OU D'AVC
Amgen's Repatha (evolocumab) received a favorable opinion from the CMUH for broader use in adults with established atherosclerotic cardiovascular disease or high risk of developing such disease. This recommendation is based on the Phase III VESALIUS-CV trial, which showed significant reduction in major cardiovascular events. If approved by the European Commission, this indication could enhance cardiovascular care in Europe.
Read more →AMGNLA OPINIÓN FAVORABLE DEL CHMP RESPALDA UN USO MÁS AMPLIO DE REPATHA® DE AMGEN
Amgen's Repatha has received a favorable opinion from the CHMP for broader use in adults at high cardiovascular risk. This recommendation is based on the phase 3 VESALIUS-CV trial, which showed significant reductions in major adverse cardiovascular events. If approved by the European Commission, Repatha could greatly benefit patients who struggle to manage LDL-C levels despite existing therapies.
Read more →AMGNPOSITIVE STELLUNGNAHME DES CHMP UNTERSTÜTZT BREITERE ANWENDUNG VON AMGENS REPATHA® VOR ERSTEM HERZINFARKT ODER SCHLAGANFALL
Amgen announced that the CHMP has issued a positive opinion for Repatha, supporting its use in adults at high risk for cardiovascular events. This recommendation is based on the VESALIUS-CV Phase 3 study, which demonstrated that Repatha significantly lowers the risk of major cardiovascular events. If approved by the European Commission, this could enhance treatment options for patients who struggle to meet LDL-C targets.
Read more →AMGNPOSITIVE CHMP OPINION SUPPORTS BROADER USE OF AMGEN'S REPATHA® BEFORE A FIRST HEART ATTACK OR STROKE
Amgen announced that the CHMP has issued a positive opinion for Repatha, supporting its use in adults at high risk for cardiovascular events. This recommendation is based on the VESALIUS-CV trial, which showed significant reductions in major cardiovascular events. If approved by the European Commission, this could expand treatment options for many patients in Europe.
Read more →AMGNAMGEN ANNOUNCES WEBCAST OF 2026 SECOND QUARTER FINANCIAL RESULTS
Amgen announced it will report its second quarter 2026 financial results on August 4, 2026, after market close. Following the report, a conference call will be held at 4:30 p.m. ET, featuring CEO Robert A. Bradway and senior management. The call will be broadcast live and archived for future access.
Read more →AMGNHarbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape
Harbour BioMed achieved a landmark victory in a patent infringement case against Amgen, with a Delaware jury ruling that Amgen willfully infringed Harbour's patent. The jury awarded Harbour $20.2 million in damages, with the possibility of trebling this amount. This ruling affirms the validity of Harbour's innovative antibody technology and sets a precedent in the global antibody patent landscape.
Read more →AMGNAMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS Amgen (NASDAQ:AMGN) today announced new data at the American Diabetes Association (ADA) 86th Scientific Sessions reinforcing its commitment to...
Amgen presented new data at the American Diabetes Association's 86th Scientific Sessions, showcasing the effectiveness of Repatha in reducing major cardiovascular events among patients with high-risk diabetes. The Phase 3 VESALIUS-CV trial results demonstrated a 29% reduction in these events when Repatha was used alongside LDL-C-lowering therapies. Additionally, real-world evidence was shared, emphasizing the need for adherence to diabetes and obesity treatments to achieve better patient outcomes. Amgen's ongoing research aims to address the interconnected challenges of cardiovascular and metabolic diseases.
Read more →AMGNAMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 47th Annual Global Healthcare Conference at 9:20 a.m. ET on Tuesday, June 9, 2026. Peter...
Amgen (NASDAQ: AMGN) will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Executives Peter Griffith and Murdo Gordon will represent the company, and the presentation will be available via webcast. Amgen is known for its innovative medicines and has a robust pipeline aimed at treating various diseases. The company has a long-standing reputation in the biotechnology industry and has been recognized for its workplace culture.
Read more →AMGNAMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026 Amgen (NASDAQ:AMGN) today announced the presentation of new data across rare autoimmune and inflammatory diseases at the European Alliance of...
Amgen presented new data on rare autoimmune diseases at the EULAR 2026 Congress, highlighting findings from the Phase 3 MITIGATE trial for UPLIZNA and real-world evidence supporting TAVNEOS. The MITIGATE trial provided insights into immunoglobulin G4-related disease, showcasing UPLIZNA's long-term safety profile and efficacy. Additionally, data from the AQUARIUS analyses confirmed that TAVNEOS helps patients manage ANCA-associated vasculitis while minimizing steroid use. These findings reflect Amgen's ongoing commitment to advancing treatments for challenging medical conditions.
Read more →AMGNEUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted marketing authorization for IMDYLLTRA® (tarlatamab) as a...
Amgen announced that the European Commission has granted marketing authorization for its novel treatment IMDYLLTRA (tarlatamab) for extensive-stage small cell lung cancer (ES-SCLC). This approval is based on the results of the DeLLphi-304 Phase 3 trial, which indicated a 40% reduction in the risk of death compared to traditional chemotherapy, along with an extension of median overall survival. Despite the promising results, the treatment does have some associated risks, particularly cytokine release syndrome, requiring careful patient monitoring during administration.
Read more →About Amgen Inc.
HeadquartersONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, 91320
Founded1980
BIOPHARMAWATCH ELITE PLUS
Trade the next AMGN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime